Decision‐tree approach to the immunophenotype‐based prognosis of the B‐cell chronic lymphocytic leukemia

Use of a nonlinear prediction method, such as machine learning, is a valuable choice in predicting progression rate of disease when applied to the highly variable and correlated biological data such as those in patients with chronic lymphocytic leukemia (CLL). In this work, decision‐tree approach to cell phenotype‐based prognosis of CLL was adopted. The panel of 33 (32 different phenotypic features and serum concentration of sCD23) parameters was simultaneously presented to the C4.5 decision tree which extracted the most informative of them and subsequently performed classification of CLL patients against the modified Rai staging system. It has been shown that substantial correlation between the percentage of expression of the CD23 molecule on CD19+ B‐cells, the level of sCD23, the percentage of CD45RA+, and the absolute number of CD4CD45RA+RO+ T‐cells and the clinical stages, exists. The prediction vector, composed of their concatenated values, was able to correctly associate 83% of the cases in the low‐risk group (Rai stage 0), 100% of the cases in the intermediate‐risk group (Rai stage I and II), and 89% of the cases in the high‐risk group (Rai stage III and IV) of CLL patients. Predictivity of this vector was 100%, 95%, and 89%, respectively. In conclusion, from the described analysis, it may be inferred that two processes play important roles in the progression rate of CLL: 1. deregulated function of the CD23 gene in B‐cells accompanied by the appearance of its cleaved product sCD23 in the sera; and 2. functionally impaired and imbalanced CD4 T‐cell subpopulations found in the peripheral blood of CLL patients. Am. J. Hematol. 59:143–148, 1998. © 1998 Wiley‐Liss, Inc.

[1]  J. Cawley,et al.  Heterogeneity of CLL: high CD23 antigen and αIFN receptor expression are features of favourable disease and of cell activation , 1988, British journal of haematology.

[2]  R. Jones,et al.  CD45RO+ T-cells immunoregulate spontaneous in vitro immunoglobulin production by normal and chronic lymphocytic leukaemia B-cells. , 1995, Leukemia & lymphoma.

[3]  F. Caligaris‐cappio B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. , 1996, Blood.

[4]  C. Borrebaeck,et al.  Human CD4+ T cells expressing CD45RA acquire the lymphokine gene expression of CD45RO+ T-helper cells after activation in vitro. , 1992, Immunology.

[5]  J. Cawley,et al.  CD23 ANTIGEN EXPRESSION IN CLL , 1989, British journal of haematology.

[6]  H. Nielsen,et al.  Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. , 1991 .

[7]  R. Weiss,et al.  Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study. , 1993, Blood.

[8]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[9]  D. Hamann,et al.  Heterogeneity of the human CD4+ T-cell population: two distinct CD4+ T-cell subsets characterized by coexpression of CD45RA and CD45RO isoforms. , 1996, Blood.

[10]  E. Montserrat,et al.  Chronic Lymphocytic Leukaemia: Proposals for a Revised Prognostic Staging System , 1981 .

[11]  C. Gasche,et al.  Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Reilly,et al.  LACK OF CORRELATION BETWEEN CELL SURFACE ACTIVATION ANTIGEN EXPRESSION AND CLINICAL STAGE IN B‐CLL , 1989, British journal of haematology.

[13]  B. Jakšić,et al.  Total Tumour Mass Score (TTM): a New Parameter in Chronic Lymphocytic Leukaemia , 1981, British journal of haematology.

[14]  J. Ross Quinlan,et al.  C4.5: Programs for Machine Learning , 1992 .

[15]  J. Bonnefoy,et al.  CD23 and B-cell activation. , 1995, Current opinion in immunology.

[16]  M. Grever,et al.  Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group , 1988, American journal of hematology.

[17]  S. Fournier,et al.  Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation. , 1994, Blood.

[18]  K. Foon,et al.  Chronic lymphocytic leukemia: new insights into biology and therapy. , 1990, Annals of internal medicine.

[19]  A. Gagro,et al.  CD21‐CD23 ligand pair expression in children with allergic asthma , 1993, Clinical and Experimental Immunology.